Table 1 Baseline characteristics
Baseline characteristics | Dapagliflozin (n = 162) | Placebo (n = 162) |
|---|---|---|
Demographics | ||
Age, years | 69 (64, 77) | 71 (63, 78) |
Women | 92 (56.8%) | 92 (56.8%) |
White | 108 (67.1%) | 109 (69.0%) |
African American | 50 (31.1%) | 47 (29.7%) |
Medical history | ||
Duration of HF, years | 3.0 (1.1, 6.5) | 3.2 (1.0, 6.6) |
Previous hospitalization for HF | 98 (60.5%) | 83 (51.2%) |
Ejection fraction, % | 60 (55, 65) | 60 (54, 65) |
Ischemic heart disease | 32 (19.8%) | 31 (19.1%) |
T2D | 90 (55.6%) | 91 (56.2%) |
AF | 82 (50.6%) | 89 (54.9%) |
ICD | 7 (4.3%) | 9 (5.6%) |
Baseline HF/CV medications | ||
ACE-I/ARB | 98 (60.5%) | 98 (60.5%) |
ARNI | 2 (1.2%) | 3 (1.9%) |
Beta-blockers | 119 (73.5%) | 116 (71.6%) |
Hydralazine | 25 (15.4%) | 18 (11.1%) |
Long-acting nitrates | 34 (21.0%) | 27 (16.7%) |
MRA | 50 (30.9%) | 68 (42.0%) |
Loop diuretics | 151 (93.2%) | 135 (83.3%) |
Lipid-lowering agents | 132 (81.5%) | 127 (78.4%) |
Anticoagulant agents | 71 (43.8%) | 84 (51.9%) |
Physical examination | ||
BMI, median IQR | 35.1 (30.4, 41.8) | 34.6 (29.7, 40.4) |
Heart rate | 70 (61, 77) | 68 (62, 75) |
Systolic blood pressure | 134 (120, 152) | 132 (118, 148) |
Baseline laboratory studies | ||
NTproBNP, pg ml–1, overall | 641 (373, 1210) | 710 (329, 1449) |
NTproBNP, pg ml–1, AF | 830 (555, 1711) | 816 (481, 1687) |
NTproBNP, pg ml–1, no AF | 438 (269, 750) | 485 (263, 1168) |
BNP, pg ml–1, overall | 137 (81, 222) | 151 (90, 254) |
BNP, pg ml–1, AF | 169 (109,255) | 151 (104, 258) |
BNP, pg ml–1, no AF | 107 (67, 179) | 161 (77, 241) |
eGFR, ml min–1 | 56 (42, 69) | 54 (41, 69) |
Hemoglobin A1c, % | 6.0 (5.6, 7.3) | 6.2 (5.6, 7.1) |
Hemoglobin, g dl–1 | 12.7 (11.5, 13.9) | 12.6 (11.6, 13.8) |
Functional measures | ||
NYHA Class II | 96 (59.3%) | 90 (55.6%) |
NYHA Class III/IV | 65 (40.1%) | 72 (44.4%) |
KCCQ-OS | 63.2 ± 20.4 | 62.3 ± 20.6 |
KCCQ-CS | 63.4 ± 19.7 | 61.8 ± 20.3 |
6MWT (m), median (IQR) | 244 (165, 329) | 244 (154, 317) |
